MannKind

MANNKIND CORP

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

MannKind Corp

Earnings

Press Releases

MannKind Corporation Reports  Second Quarter 2025 Financial Results And  Provides Business Update

News

Financing

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Biotech

General

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

MannKind to Present at Upcoming Investor Conferences

Small Cap

Management

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Health Care

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

MNKD

SCPH

UTHR

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Biohaven

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Immunome

Janux Therapeutics

Nanobiotix

NuCana

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Arcus Biosciences

Sana Biotechnology

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Spyre Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

HC Wainwright & Co.

Oppenheimer

Wells Fargo

RBC Capital

Mizuho

Comments

MannKind

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL